Belite Bio, Inc. announced positive developments regarding its lead drug candidate, Tinlarebant, for treating Stargardt disease (STGD1) and ongoing trials for geographic atrophy (GA). Following an ...
MedPage Today on MSN
Immuno-Oncology Tops Embolization for Intermediate-Grade Liver Cancer
SAN FRANCISCO -- An immuno-oncology (IO) regimen for intermediate-stage hepatocellular carcinoma (HCC) significantly extended ...
SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal, ...
Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid ®-ineligible patients, representing a significant population with ...
- Mirum to host conference call to discuss analyses, today, June 17 at 8:30 a.m. ET/5:30 a.m. PT FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced ...
Windtree Therapeutics, Inc. announced that it is preparing for an interim analysis of its SEISMiC C Phase 2 study of istaroxime, targeting results for July 2025. This global, placebo-controlled, ...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for ...
- REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback